Progress of gemcitabine plus nab-paclitaxel in treatment of metastatic pancreatic cancer / 中国药学杂志

ABSTRACT

Pancreatic cancer is recognized as one of the highly malignant diseases. Its morbidity is almost equal to the annual mortality. To review the progress of the research on combination therapy of gemcitabine plus nab - paclitaxel in the treatment of pancreatic cancer, the phase II/III clinical trials of gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in recent years were reviewed and analyzed. Gemcitabine plus nab-paclitaxel has shown exciting effect on metastatic tumor recently. This chemotherapy regimen can improve not only the overall survival but also the progression - free survival of the patients, which brings a ray of dawn for the treatment of pancreatic cancer.